Evercore ISI Group Downgrades NovoCure to In-Line, Announces $90 Price Target

Evercore ISI Group analyst Vijay Kumar downgrades NovoCure (NASDAQ:NVCR) from Outperform to In-Line and announces $90 price target.

Benzinga · 01/02/2020 12:24

Evercore ISI Group analyst Vijay Kumar downgrades NovoCure (NASDAQ:NVCR) from Outperform to In-Line and announces $90 price target.